heart patient

For Patients

Heart failure is a complex disease which develops over time. Patients are treated following well established guidelines[1],[2] which are revised on a regular basis and the revisions are made based on new scientific understanding.
 
Heart failure hospitalizations represent 1% to 2% of all hospital admissions[3] and heart failure is the most common diagnosis in hospitalized patients aged >65 years[4]. For a more detailed review of the epidemiology of heart failure, please refer to the article of Groenewegen et al.[5].
 
The decision pathway for treating heart failure patients with reduced ejection fraction is complex and consists of several important considerations[6],[7]. One approach to managing heart failure patients with reduced ejection fraction (HFrEF) is using bi-ventricular pacemakers (cardiac resynchronization therapy – CRT) which holds a Class I recommendation with level A evidence for certain patients. The ESC guidelines states that “assessing the ‘response’ to CRT is challenging. The extent of reverse remodeling is one of the most important mechanisms of action of CRT.”
 
The figure below shows the documented response rate to a CRT implantation in heart failure patients.


CRT response rate in heart failure patients: around 60% of all patients are responders whereas 30% are non-responders and 10% are negative responders. Pacertool is aiming to further improve the efficacy in the responder group and to be able to detect the patients who are non- or negative responders.


Pacertool addresses this problem with a technology which has the potential to improve CRT response rates. The technology consists of an intra-cardiac catheter, a signal amplifier and a software which displays important characteristics of left ventricular synchrony. Through upcoming clinical trials, the company will investigate if the measured characteristics improve the effectiveness of CRT implantations.

Please note that the Pacertool’s technology is not approved for any clinical trials at the current time-point nor is it approved for ordinary clinical use in any geography. The previous description is a lay description of the Pacertool technology and how it potentially may improve the treatment for certain heart failure patients.

If you are interested to support Pacertool by sharing your experience as an HFrEF patient or want to participate in our patient engagement activities, please email us at patientengagement@pacertool.com. We look forward to hearing from you.